Note 10 - Grants and Collaboration Revenue

9 Months Ended

Sep. 30, 2017

Government Grants and Contracts [Text Block]

10 .	Grants and Collaboration Revenue

Government Grants and Contracts

We receive payments from government entities under our grants and contrac

ts with the National Institute of Allergy and Infectious Diseases in support of certain of our vaccine research and development efforts. We record revenue associated with government grants and contracts as the reimbursable costs are incurred. During the

three

-month and

nine

-month periods ended

September 30, 2017,

we recorded

$247,994

and

$800,866,

respectively, of revenues associated with these grants and contracts, as compared to

$440,106

and

$653,986,

respectively, for the comparable periods of

2016.

As of

September 30, 2017,

there is an aggregate of

$744,769

in approved grant and contract funds available for use.

Collaboration Revenue

March 2017,

we entered into a clinical trial collaboration agreement with American Gene Technologies International, Inc. (“AGT”) whereby AGT intends to conduct a phase

human clinical trial investigating our combined technologies as a func

tional cure for HIV infection. In connection with the agreement, during the

second

quarter of

2017

AGT paid to us a non-refundable fee of

$95,000,

which we recorded as collaboration revenue during the

nine

-month period ended

September 30, 2017.